• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝巨噬细胞活化：与代谢相关脂肪性肝病患者肝脏组织病理学变化的关系

Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease.

作者信息

Hegazy Doaa H, Mohamed Fathalla S, Mahmoud Sabah A H, El Deeb Nevine M F, Elyamany Amany S, Elgendi Ahmed M

机构信息

Egypt Ministry of Health, Egypt.

Internal Medicine Department, Hepatology Unit, Faculty of Medicine, Alexandria University, Egypt.

出版信息

Clin Exp Hepatol. 2024 Mar;10(2):79-89. doi: 10.5114/ceh.2024.139983. Epub 2024 Jun 11.

DOI:10.5114/ceh.2024.139983
PMID:39845348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11748224/
Abstract

AIM OF THE STUDY

Metabolic associated steatotic liver disease (MASLD) is one of the most frequent chronic liver diseases in the world; macrophage activation is reflected by increased expression of CD163, which sheds as serum soluble CD163 that is linked to hepatic steatosis, inflammation, and fibrosis. Aim of the study was assessment of liver macrophage activation and hepatic histopathological changes in patients with MASLD.

MATERIAL AND METHODS

A total of 30 patients with MASLD and equal numbers of age- and sex-matched healthy controls were enrolled in the study. Quantitative serum levels of soluble CD163 (sCD163) were determined using a commercially available standard sandwich ELISA kit. Core liver biopsies were obtained from patients with MASLD and evaluation of CD163 using anti-CD163 Ab-1 (Clone 10D6) - mouse monoclonal antibody.

RESULTS

The median sCD163 level was significantly higher in patients with MASLD compared with healthy controls. It can discriminate patients with MASLD from healthy controls at a cut-off value of 814 pg/ml. sCD163 level and intrahepatic total CD163-positive cell count were positively correlated, and both showed positive correlations with nonalcoholic fatty liver disease activity score.

CONCLUSIONS

Soluble CD163 can discriminate MASLD patients from healthy controls after the exclusion of other causes of inflammation.

摘要

研究目的

代谢相关脂肪性肝病（MASLD）是全球最常见的慢性肝病之一；巨噬细胞活化通过CD163表达增加得以体现，CD163可脱落为血清可溶性CD163，其与肝脏脂肪变性、炎症及纤维化相关。本研究的目的是评估MASLD患者肝脏巨噬细胞活化及肝脏组织病理学变化。

材料与方法

本研究共纳入30例MASLD患者以及数量相等、年龄和性别匹配的健康对照。使用市售标准夹心ELISA试剂盒测定血清可溶性CD163（sCD163）的定量水平。从MASLD患者获取肝脏核心活检组织，并使用抗CD163 Ab-1（克隆号10D6）小鼠单克隆抗体评估CD163。

结果

与健康对照相比，MASLD患者的sCD163水平中位数显著更高。在截断值为814 pg/ml时，它能够区分MASLD患者与健康对照。sCD163水平与肝内CD163阳性细胞总数呈正相关，且二者均与非酒精性脂肪性肝病活动评分呈正相关。

结论

在排除其他炎症原因后，可溶性CD163能够区分MASLD患者与健康对照。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/0095063a7af5/CEH-10-54195-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/a543bc044dc3/CEH-10-54195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/8af93d155749/CEH-10-54195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/4d06d7b82f80/CEH-10-54195-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/0095063a7af5/CEH-10-54195-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/a543bc044dc3/CEH-10-54195-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/8af93d155749/CEH-10-54195-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/4d06d7b82f80/CEH-10-54195-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6036/11748224/0095063a7af5/CEH-10-54195-g004.jpg

相似文献

1
Liver macrophage activation: Relation with hepatic histopathological changes in patients with metabolic associated steatotic liver disease.肝巨噬细胞活化：与代谢相关脂肪性肝病患者肝脏组织病理学变化的关系
Clin Exp Hepatol. 2024 Mar;10(2):79-89. doi: 10.5114/ceh.2024.139983. Epub 2024 Jun 11.
2
A comparative genomic study across 396 liver biopsies provides deep insight into FGF21 mode of action as a therapeutic agent in metabolic dysfunction-associated steatotic liver disease.一项针对396份肝活检样本的比较基因组研究，为深入了解成纤维细胞生长因子21（FGF21）作为代谢功能障碍相关脂肪性肝病治疗药物的作用模式提供了依据。
Clin Transl Med. 2025 Feb;15(2):e70218. doi: 10.1002/ctm2.70218.
3
Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.可溶性 CD163 和甘露糖受体与慢性乙型肝炎活动和纤维化相关，并随着治疗而下降。
J Gastroenterol Hepatol. 2018 Feb;33(2):484-491. doi: 10.1111/jgh.13849.
4
Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.接受减肥手术的病态肥胖患者中巨噬细胞活化标志物可溶性CD163与非酒精性脂肪性肝病
J Gastroenterol Hepatol. 2015 Aug;30(8):1293-300. doi: 10.1111/jgh.12943.
5
Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro.可溶性 CD163 在内脏脂肪和脂肪变性肝中没有增加，甚至在体外被游离脂肪酸抑制。
Exp Mol Pathol. 2011 Dec;91(3):733-9. doi: 10.1016/j.yexmp.2011.07.005. Epub 2011 Aug 3.
6
Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.隐匿性脂肪性肝病患者的肝脏与动脉粥样硬化风险。
Hepatol Int. 2024 Jun;18(3):943-951. doi: 10.1007/s12072-023-10624-8. Epub 2024 Jan 16.
7
The predictive value of triglyceride-glucose-high density lipoprotein-body mass index (TGH-BMI) for different degrees of hepatic steatosis and liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD).甘油三酯-葡萄糖-高密度脂蛋白-体重指数（TGH-BMI）对代谢功能障碍相关脂肪性肝病（MASLD）不同程度肝脂肪变性和肝纤维化的预测价值
Clin Nutr ESPEN. 2025 Apr;66:290-301. doi: 10.1016/j.clnesp.2025.01.041. Epub 2025 Jan 24.
8
Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.慢性肾脏病发生时代谢功能障碍相关脂肪/脂肪变性肝病的严重程度和缓解情况。
J Am Heart Assoc. 2024 Mar 5;13(5):e032604. doi: 10.1161/JAHA.123.032604. Epub 2024 Feb 23.
9
Complement 3a receptor 1 on macrophages and Kupffer cells is not required for the pathogenesis of metabolic dysfunction-associated steatotic liver disease.巨噬细胞和库普弗细胞上的补体3a受体1对于代谢功能障碍相关脂肪性肝病的发病机制并非必需。
Elife. 2025 Jan 8;13:RP100708. doi: 10.7554/eLife.100708.
10
Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in nonalcoholic steatohepatitis.可溶性 CD163 是预测非酒精性脂肪性肝炎纤维化和肝细胞癌发展的指标。
BMC Gastroenterol. 2023 May 10;23(1):143. doi: 10.1186/s12876-023-02786-4.

本文引用的文献

1
Obese Patients With Nonalcoholic Fatty Liver Disease Have an Increase in Soluble Plasma CD163 and a Concurrent Decrease in Hepatic Expression of CD163.患有非酒精性脂肪性肝病的肥胖患者血浆可溶性CD163增加，同时肝脏CD163表达减少。
Gastro Hep Adv. 2023 Mar 8;2(5):711-720. doi: 10.1016/j.gastha.2023.03.006. eCollection 2023.
2
Natural history of metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的自然史。
Eur J Intern Med. 2024 Apr;122:3-10. doi: 10.1016/j.ejim.2023.11.005. Epub 2023 Nov 7.
3
Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
代谢功能障碍相关性脂肪性肝病及其病理生理学、与动脉粥样硬化和心血管疾病的关联，以及治疗方法。
Int J Mol Sci. 2023 Oct 23;24(20):15473. doi: 10.3390/ijms242015473.
4
Familial coaggregation of MASLD with hepatocellular carcinoma and adverse liver outcomes: Nationwide multigenerational cohort study.MASLD 伴肝细胞癌的家族聚集性及不良肝脏结局：全国多代队列研究。
J Hepatol. 2023 Dec;79(6):1374-1384. doi: 10.1016/j.jhep.2023.08.018. Epub 2023 Aug 28.
5
Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis.胰岛素抵抗与脂肪组织相互作用是代谢（功能）障碍相关脂肪性肝病发病机制的基础。
World J Gastroenterol. 2023 Jul 7;29(25):3999-4008. doi: 10.3748/wjg.v29.i25.3999.
6
Pathophysiology of obesity and its associated diseases.肥胖及其相关疾病的病理生理学
Acta Pharm Sin B. 2023 Jun;13(6):2403-2424. doi: 10.1016/j.apsb.2023.01.012. Epub 2023 Jan 13.
7
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识：新脂肪性肝病命名。
Ann Hepatol. 2024 Jan-Feb;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub 2023 Jun 24.
8
Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.肥胖、非酒精性脂肪性肝病和肝细胞癌：现状和治疗靶点。
Front Endocrinol (Lausanne). 2023 Jun 8;14:1148934. doi: 10.3389/fendo.2023.1148934. eCollection 2023.
9
The Multifaceted Roles of Macrophages in NAFLD Pathogenesis.巨噬细胞在非酒精性脂肪性肝病发病机制中的多方面作用。
Cell Mol Gastroenterol Hepatol. 2023;15(6):1311-1324. doi: 10.1016/j.jcmgh.2023.03.002. Epub 2023 Mar 11.
10
Hepatic macrophages: Key players in the development and progression of liver fibrosis.肝脏巨噬细胞：肝纤维化发生和发展中的关键角色。
Liver Int. 2021 Oct;41(10):2279-2294. doi: 10.1111/liv.14940. Epub 2021 May 24.